Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tibet Cheezheng Tibetan Medicine Co (002287) Fair Value & Analysis

Healthcare · CN · Market cap 11.7B CNY

Price¥19.38
Fair Value¥21.72
Upside+12.1%
Quality94/100
Evidence: High Range ¥15.13 – ¥27.39

Analysis

Tibet Cheezheng Tibetan Medicine Co (002287) currently trades at ¥19.38, while our model-based Fair Value estimate is ¥21.72 — implying the stock looks roughly 12.1% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China and internationally. The company also provides plasters, topical and oral tibetan medicines, and ointments. Its products are used in areas of orthopedics, neurology, dermatology, granules, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculoskeletal system, nervous system, respiratory, digestive, urinary, and cerebrovascular sectors. The company was founded in 1995 and is based in Nyingchi, China. Tibet Cheezheng Tibetan Medicine Co., Ltd. is a subsidiary of Gansu Qizheng Industry Group Co., Ltd.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.